Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Large Drop in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 65,013 shares, a decline of 42.7% from the January 29th total of 113,501 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 442,397 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 442,397 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Sysmex Stock Performance

Sysmex stock opened at $9.38 on Friday. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $5.90 billion, a price-to-earnings ratio of 19.54 and a beta of 1.14. Sysmex has a 12-month low of $8.15 and a 12-month high of $19.85. The stock has a 50-day simple moving average of $9.54 and a 200 day simple moving average of $10.82.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $837.32 million for the quarter, compared to analyst estimates of $819.99 million. Sysmex had a return on equity of 9.32% and a net margin of 8.86%. On average, research analysts anticipate that Sysmex will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.